Dyslipidemia and cardiovascular disease in women

Area of Science:

• Cardiology
• Endocrinology
• Women's Health

Background:

• Cardiovascular disease (CVD) is a primary cause of mortality in developed nations, disproportionately affecting women.
• Dyslipidemia, characterized by abnormal blood lipid levels, is highly prevalent in women, especially after menopause.
• Menopause is linked to adverse lipid profile changes, including increased LDL-cholesterol and decreased HDL-cholesterol.

Purpose of the Study:

• To review the role of dyslipidemia in cardiovascular risk in women.
• To evaluate the efficacy of lipid-lowering therapies in women.
• To discuss current guidelines for managing dyslipidemia in women.

Main Methods:

• Review of current literature and meta-analyses on dyslipidemia and cardiovascular disease in women.
• Analysis of gender-specific outcomes from major lipid-lowering drug trials.
• Examination of recommendations from recent clinical guidelines.

Main Results:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a key lipid parameter in both genders.
• HDL-cholesterol and triglycerides may have a stronger association with cardiovascular risk in women.
• Statin therapy and ezetimibe/simvastatin combinations demonstrate similar benefits in women and men.
• Hormone replacement therapy is not recommended for CVD prevention in women.

Conclusions:

• Lipid management for dyslipidemia in women is largely consistent with that in men.
• Risk stratification is crucial before initiating lipid-lowering treatments in women without established cardiovascular disease.
• Current guidelines emphasize a cautious approach to avoid overtreatment in asymptomatic women.